Filtered By:
Condition: Bleeding
Management: Healthcare Costs

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 30 results found since Jan 2013.

Abstract 301: Healthcare Costs Following Stroke and Major Bleeding Events in Nonvalvular Atrial Fibrillation Patients Session Title: Poster Session III
Conclusions: NVAF patients who have a stroke or MB event incur higher healthcare costs relative to patients without events. Interventions preventing stroke or MB events have the potential to reduce the healthcare burden associated NVAF.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Naccarelli, G., Stokes, M., DeLeon, A., Tate, N., Wang, R., Wang, A., Fredell, J. Tags: Session Title: Poster Session III Source Type: research

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
CONCLUSIONS SSRIs appeared to improve dependence, disability, neurological impairment, anxiety and depression after stroke, but there was heterogeneity between trials and methodological limitations in a substantial proportion of the trials. Large, well-designed trials are now needed to determine whether SSRIs should be given routinely to patients with stroke. PMID: 23903272 [PubMed - in process]
Source: Sao Paulo Medical Journal - August 3, 2013 Category: Journals (General) Authors: Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, Hacklett ML Tags: Sao Paulo Med J Source Type: research

Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants.
CONCLUSIONS: The incremental healthcare costs incurred by patients with versus without stroke/SE was nearly twice as high as those of patients with versus without MB. Moreover, each additional year up to 4 years after the first event was associated with an incremental cost for patients with a stroke/SE or MB event compared to those without an event. PMID: 30939954 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - April 5, 2019 Category: Health Management Tags: J Med Econ Source Type: research

An electronic decision support tool for Stroke Prevention in Atrial Fibrillation (SPAF): An integrated primary-tertiary care model of care. (S47.001)
CONCLUSIONS: Given that the existing technology base is well established nationwide, it is expected that this could become a national model which would have significant benefits for patient care and healthcare costs across the country.Disclosure: Dr. Jolliffe has nothing to disclose. Dr. Rosemergy has nothing to disclose. Dr. Lanford has nothing to disclose. Dr. Abernethy has nothing to disclose. Dr. Ranta has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Jolliffe, E., Rosemergy, I., Lanford, J., Abernethy, D., Ranta, A. Tags: Cerebrovascular Disease and Interventional Neurology Source Type: research

Implications of stroke and bleeding risk-scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.
CONCLUSION: NVAF patients accrue variable healthcare costs. Stroke and bleeding risk should be taken into account during the creation of NVAF payment bundles. PMID: 29164990 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - November 23, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

'Not enough over-50s' taking aspirin to prevent heart disease
Conclusion This study doesn't really tell us anything we didn't already know. Aspirin has been used for many years to prevent heart attacks and strokes in people with cardiovascular disease. Aspirin's wider use is controversial, because of the potential side effects. What this study does add is an estimate of what might happen if all people in the US who were advised to take aspirin under US guidelines, actually did so. (The researchers say that 40% of men and 10% of women advised to take aspirin don't take it). The study assumes that people would get the same benefits as those seen in clinical trials of aspirin. This is u...
Source: NHS News Feed - December 1, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Older people Source Type: news

Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients.
Conclusion: Elderly patients with NVAF in the U.S. who continued with apixaban treatment had a lower risk of MB-related hospitalization and lower MB- and stroke/SE-related medical costs compared to patients who switched to another OAC. PMID: 31120309 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - May 25, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy
Conclusions: Allowing for differences in prescribing practice, AF/AFL patients treated with W+A are at higher risk of stroke and arterial embolism, and have higher healthcare use and costs, than patients receiving W+OAAD.
Source: International Journal of Cardiology - February 15, 2012 Category: Cardiology Authors: Annie Guérin, Jay Lin, Mehul Jhaveri, Eric Q. Wu, Andrew P. Yu, Martin Cloutier, Genevieve Gauthier, Joseph S. Alpert Tags: Original Articles Source Type: research

Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
ConclusionsMorbidly obese AF patients treated with rivaroxaban had comparable risk of ischemic stroke/systemic embolism and major bleeding as those treated with warfarin, but lower healthcare resource utilization and costs.
Source: American Heart Journal - February 21, 2019 Category: Cardiology Source Type: research

Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
ConclusionPatients with NVAF and  ≥ 6 comorbid conditions had significantly different risks for stroke/SE and MB when comparing DOACs to DOACs, and different healthcare expenses. This study's results may be useful for evaluating the risk–benefit ratio of DOAC use in patients with NVAF and multimorbidity.
Source: Advances in Therapy - December 17, 2022 Category: Drugs & Pharmacology Source Type: research

Clinical and Economic Outcomes among Elderly Myocardial Infarction Survivors in the United States
ConclusionsRisks of mortality and cardiovascular events remain high in a Medicare population surviving >1 year after a MI. Continuing healthcare costs are doubled over pre‐MI levels up to five years after an MI. Secondary prevention measures beyond the acute post‐MI period may be indicated to reduce risk and cost in this chronic disease phase.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - July 31, 2016 Category: Cardiology Authors: Erru Yang, Michael Stokes, Saga Johansson, Carl Mellstr öm, Elizabeth Magnuson, David J. Cohen, Phillip Hunt Tags: Original Research Article Source Type: research

Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation
ConclusionsThe proportions of patients with non-valvular atrial fibrillation who were not prescribed an oral anticoagulant decreased but remained high. We observed an increase in direct oral anticoagulant use that coincided with decreased incidence of clinical outcomes as well as decreasing total healthcare costs.
Source: Journal of Thrombosis and Thrombolysis - August 2, 2023 Category: Hematology Source Type: research

Abstract 250: Economic Burden of Mortality and Cardiovascular Events among Patients with Acute Coronary Syndromes in a Commercial Health Plan Poster Session III
Conclusion: Our findings suggest that a modest 10% increase in anticoagulant use among patients with ACS would reduce mortality, MI, ST and related healthcare costs by 4%, 0.7%, and 3%, respectively. Addition of anticoagulation therapy potentially reduces the incidence of ACS-related mortality, MI, ST and associated healthcare costs to a commercial health plan, and benefits from anticoagulation use should be balanced against the risk of bleeding.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Ogden, K., Patel, A. A., Mody, S. H., Veerman, M., Crivera, C., Quock, T. P. Tags: Poster Session III Source Type: research

Direct healthcare costs and cost-effectiveness of acute coronary syndromes secondary prevention with ticagrelor compared to clopidogrel - economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
CONCLUSIONS: In lifelong time horizon, which should be used in case of comparison of technologies with different impact on mortality, cost-effectiveness evaluation resulted in more favourable economic outcomes for ticagrelor than for generic clopidogrel with the cost per QALY well below recommended willingness to pay (WTP) threshold in Poland (24 965 PLN vs. 111 381 PLN). PMID: 24846362 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - May 20, 2014 Category: Cardiology Authors: Pawęska J, Macioch T, Perkowski P, Budaj A, Niewada M Tags: Kardiol Pol Source Type: research

Abstract 175: Atrial Fibrillation in the USF Resident Clinics: Quality-Driven Medical Therapy Session Title: Poster Session AM
Patients with atrial fibrillation (afib) have a high rate of serious complications including stroke and decompensated heart failure. While patients with afib are five times more likely to suffer a stroke in their lifetime than the general population, this risk can be reduced by 64% with appropriate anticoagulation using warfarin or approved novel oral anticoagulants (NOACs). Reducing the morbidity and mortality from excess strokes is a common interest nationwide due to unsustainable healthcare costs, increasing human resource gaps in medicine, and payment reforms that hold physicians and healthcare organizations financiall...
Source: Circulation: Cardiovascular Quality and Outcomes - April 5, 2018 Category: Cardiology Authors: Sadic, E. Tags: Session Title: Poster Session AM Source Type: research